Share ownership Genmab A/S Nasdaq

GMAB

US3723032062

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-08-13 EDT			5-day change	1st Jan Change
31.34 ^USD	-0.25%		+7.11%	+1.75%

08-12	BNP Paribas Initiates Genmab at Outperform, With $40 Price Target	MT
08-12	Nordic stocks in North America: AstraZeneca fell 1.0%	FW

Share class: Genmab A/S

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	62,353,252	59,493,589 ( 95.41 %)	915,601 ( 1.468 %)	95.41 %

Major shareholders: Genmab A/S

Name	Stocks	%	Valuation
Orbis Investment Management Ltd. 2.073 %	12,925,578	2.073 %	373 M $
AllianceBernstein LP 1.533 %	9,557,149	1.533 %	276 M $
Paradigm BioCapital Advisors LP 1.278 %	7,967,836	1.278 %	230 M $
Arrowstreet Capital LP 0.7979 %	4,975,324	0.7979 %	144 M $
Aperio Group LLC 0.7104 %	4,429,714	0.7104 %	128 M $
Renaissance Technologies LLC 0.708 %	4,414,550	0.708 %	127 M $
Deep Track Capital LP 0.5875 %	3,663,250	0.5875 %	106 M $
Harding Loevner LP 0.5183 %	3,231,601	0.5183 %	93 M $
First Trust Advisors LP 0.4421 %	2,756,522	0.4421 %	80 M $
Deerfield Management Co. LP (Private Equity) 0.3948 %	2,462,000	0.3948 %	71 M $
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Stocks	%	Valuation
Orbis Investment Management Ltd. 5.693 %	3,549,674	5.693 %	1 015 M $
GENMAB A/S 4.437 %	2,766,533	4.437 %	791 M $
Jan van de Winkel 1.057 %	658,932	1.057 %	188 M $
AllianceBernstein Investments Taiwan Ltd. 0.7348 %	458,160	0.7348 %	131 M $
Robert W. Baird & Co., Inc. (Equity) 0.4639 %	289,270	0.4639 %	83 M $
Nykredit Bank A/S (Investment Management) 0.4126 %	257,249	0.4126 %	74 M $
ÖKOWORLD LUX SA 0.2245 %	140,000	0.2245 %	40 M $
Carmignac UK Ltd. 0.2061 %	128,535	0.2061 %	37 M $
Sjunde AP-fonden 0.166 %	103,520	0.166 %	30 M $
Svenska Handelsbanken AB (Denmark) 0.096 %	59,870	0.096 %	17 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	134.92%
Others	8.86%
Genmab A/S	4.44%
Individuals	1.12%
SEI Investments Co.	0.15%
Fifth Third Bancorp	0.08%
Regions Financial Corp.	0.02%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	108.46%
Bermuda	26.43%
Denmark	5.01%
Switzerland	2.21%
United Kingdom	2.11%
France	1.21%
Individuals	1.12%
Taiwan	0.73%
Norway	0.38%
Ireland	0.36%
Luxembourg	0.28%
Canada	0.24%
Germany	0.23%
Sweden	0.17%
Australia	0.07%
Italy	0.07%
Cayman Islands	0.07%
Japan	0.06%
Finland	0.06%
Spain	0.06%
Belgium	0.05%
Austria	0.05%
Singapore	0.04%
Hong Kong	0.03%
China	0.02%
Portugal	0.02%
Netherlands	0.02%
Liechtenstein	0.01%
New Zealand	0.01%
South Africa	0.01%
South Korea	0.01%

Based on 1000 largest holdings

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).

Employees

3,119

Sector

Biotechnology & Medical Research

Calendar

11-04 Earnings release - Q3 2026

More about the company